Background: Over 80 years ago Fuller Albright reported a vitamin D-resistant form of rickets, which is likely the initial description of X-linked hypophosphatemia (XLH). Recently the genetic basis of the disease has been identified and a more complete understanding of the pathophysiology has emerged. Purpose: To increase awareness of the latest published data on the genetics, clinical manifestations, differential diagnoses, biochemical findings, as well as growth and development of patients with XLH. Description of Topic: XLH is a rare, progressive, life-long disorder and the most common form of heritable rickets. The estimated prevalence of XLH is 1:20,000 to 1:25,000. XLH is caused by loss-of-function mutations in the phosphate regulating endopeptidases on the X-chromosome (PHEX) gene, leading to high circulating levels of fibroblast growth factor 23 (FGF23). Over 300 PHEX mutations have been reported. An X-linked dominant inheritance pattern is typical; however, de novo PHEX mutations are reported in up to 20-30% of the cases. Excess FGF23 increases urinary phosphate losses with consequent hypophosphatemia, resulting in rickets and osteomalacia. Clinical manifestations may include lower limb deformities, short stature, bone and joint pain, dental abscesses, delayed walking, and gait abnormalities. Neurological features may include Chiari 1 malformation and craniosynostosis. Low serum phosphate levels, a low renal tubular threshold for phosphate reabsorption (TmP/GFR), and low or normal circulating 1,25(OH)2D are characteristic biochemical findings in patients with XLH. The symptoms of XLH vary among individuals and while there is similar pathophysiology for children and adults, clinical manifestations can differ. Debilitating consequences in adults include osteoarthritis, enthesopathy, spinal stenosis and pseudofractures. In addition, complications of conventional medical therapy (phosphate salts and active vitamin D analogs) include nephrocalcinosis and hyperparathyroidism. Clinical Implications: Previously, XLH was considered a disorder that manifests only during growth; however, adolescent patients require attention along with a smooth transition to adult care. In addition, recognition of the complex disease features of XLH is essential for accurate diagnosis and management. Pediatric endocrine nurses are well qualified to provide the latest disease state education to patients and families, and to encourage routine clinical evaluation to assess treatment response, disease progression, and therapeutic complications.
Read full abstract